BBB Shuttle Candidate Screening Intracranial Parameter Evaluation Dose Range Determination and Optimization

Research on pDC Functional Regulation Construction of Autoimmune Disease Models Exploration of Antiviral Immune Mechanisms Regulation of Tumor Immune Microenvironment Evaluation of Immunotherapy Target Efficacy

Pancreatic Development and Regeneration Research: Investigate the role of human Pdx1 in the differentiation of pancreatic progenitor cells, islet development, and β-cell functional maturation. Explore the molecular mechanisms by which Pdx1 regulates pancreatic regeneration and repair, and evaluate its potential in treating diabetes. Diabetes Research: Study the mechanisms by which Pdx1 dysfunction leads to β-cell dysfunction and insulin secretion defects. Evaluate the feasibility of improving β-cell function and treating diabetes through gene therapy or pharmacological interventions that regulate Pdx1 expression. Pancreatic Cancer Research: Explore the role of Pdx1 in the initiation, progression, and maintenance of pancreatic tumors such as pancreatic ductal adenocarcinoma. Investigate the potential of targeting the Pdx1 signaling pathway or regulating its expression as a novel strategy for pancreatic cancer treatment. Endocrine Metabolic Disease Modeling: Utilize Pdx1 humanized mice to establish disease models (e.g., diabetes, pancreatic hypoplasia) that more closely resemble human diseases. Evaluate the application value of cell therapies and gene therapies based on human Pdx1 in the treatment of metabolic diseases.

Cellular Signaling and Microenvironment Regulation Research: Investigate the functions of human Simp protein in mediating intercellular interactions, signal transduction, and maintaining microenvironment homeostasis. Explore the mechanisms by which Simp regulates communication between stromal cells, immune cells, and tumor cells. Tumor Biology and Therapy Research: Study the expression patterns of Simp in the tumor microenvironment and its impact on tumor growth, invasion, metastasis, and angiogenesis. Evaluate the potential of antibodies, small molecule inhibitors, or gene therapies targeting human Simp in tumor treatment. Inflammation and Autoimmune Disease Research: Investigate the expression and function of Simp in acute and chronic inflammatory responses, tissue repair, and fibrosis processes. Explore strategies for targeting Simp to regulate inflammatory pathways in the treatment of autoimmune and inflammatory diseases. Tissue Regeneration and Repair Research: Study the role of Simp in tissue damage repair, regenerative medicine, and stem cell niche maintenance. Assess the application value of modulating the Simp signaling pathway in promoting tissue regeneration and functional recovery.

Immune Checkpoint Function and Mechanism Research: Investigate the expression patterns and regulatory mechanisms of human Vstm3 (V-set and transmembrane domain-containing protein 3) in immune cells such as T cells and NK cells. Explore the role of Vstm3 as a novel immune checkpoint molecule in suppressing immune responses and maintaining immune tolerance. Tumor Immunotherapy Evaluation: Evaluate the efficacy of blocking antibodies, antagonists, or agonists targeting human Vstm3 in tumor immunotherapy. Study the expression of Vstm3 in the tumor microenvironment and its impact on the function of tumor-infiltrating lymphocytes, exploring combination immunotherapy strategies. Autoimmune and Inflammatory Disease Research: Investigate the role of Vstm3 in the development and progression of autoimmune diseases (e.g., rheumatoid arthritis, multiple sclerosis). Test the potential of therapeutic strategies targeting Vstm3 in regulating excessive immune responses and alleviating autoimmune pathology. Infectious Immunity and Vaccine Research: Study the regulatory role of Vstm3 in adaptive immune responses during acute and chronic infections. Assess the application value of intervention strategies targeting Vstm3 in enhancing anti-infective immunity and improving vaccine efficacy.

Antibody Drug Evaluation and Development: Evaluate the in vivo efficacy, pharmacokinetics, and safety of therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting human transferrin receptor 1 (TFRC/CD71). Optimize the design of antibody drugs targeting TFRC and assess their tumor targeting specificity and therapeutic window. Drug Delivery System Research: Leverage the high expression of TFRC in tumor cells to study the tumor enrichment capacity and efficacy of TFRC-targeted drug delivery systems (e.g., liposomes, nanoparticles). Evaluate the efficiency of TFRC-mediated drug internalization and intracellular release kinetics. Tumor Biology and Therapy Research: Investigate the role of TFRC in tumor initiation, progression, proliferation, and metastasis, as well as its regulatory mechanisms. Assess the efficacy and potential resistance mechanisms of TFRC-targeted therapies in solid tumors and hematological malignancies. Iron Metabolism and Related Disease Research: Study the effects of human TFRC on iron uptake, transport, and homeostasis regulation in mice. Explore the role of TFRC dysfunction in diseases such as iron overload and anemia.

1. Th2 Immune Response and Allergic Disease Research: Simulating the biological function of human interleukin-4 (IL-4) to study its core role in Th2 cell differentiation, B cell class switching (production of IgE and IgG1), eosinophil activation, and allergic reactions (such as asthma, atopic dermatitis, food allergy). Evaluating the in vivo efficacy and mechanism of anti-inflammatory/anti-allergic therapies targeting human IL-4 or IL-4 receptor (such as Dupilumab). 2. Tumor Immunity and Immune Therapy Assessment: Studying the role of human IL-4 in the tumor microenvironment, particularly its effects on tumor-associated macrophages (TAMs) polarization, regulatory T cell (Treg) function, and anti-tumor immune response. Assessing the potential of targeting the IL-4/IL-4R axis in tumor immunotherapy (such as combined checkpoint inhibitors). 3. Parasitic Infection and Immunity: Exploring the role of human IL-4 in the Th2-type immune response and tissue repair against parasitic infections (such as worms).

1. T cell immunotherapy development: Evaluate the function, efficacy, and safety of T cell-based immunotherapies (such as T cell connectors, T cell receptor mimetics, T cell activation antibodies, etc.). Test the efficacy of bispecific antibodies targeting CD3 (such as targeting CD3x tumor antigens) in the recruitment and activation of T cells. 2. Tumor immunotherapy research: Evaluate the synergistic antitumor effects of combination therapies (such as T cell connectors with immune checkpoint inhibitors, and adoptive T cell therapy in combination). Explore the regulatory mechanisms of T cell activation, exhaustion, and function in the tumor microenvironment. 3. Autoimmune and inflammatory disease research: Study the role of CD3E in autoimmune diseases mediated by abnormal activation of T cells (such as rheumatoid arthritis, type 1 diabetes, etc.). Test the application of T cell-targeted therapies in immune regulation and tolerance induction.

1. Macrophage Immunotherapy Development: Evaluate the efficacy and safety of drugs targeting the CD47-SIRPα axis (such as SIRPα fusion proteins, antibodies). Study the mechanisms and enhancement strategies of antibody-dependent cellular phagocytosis (ADCP) mediated by macrophages. 2. Tumor Immunology: Simulate the immune regulatory function of SIRPα in the human body, and study its regulation of macrophage phagocytosis. Test the synergistic effects of SIRPα-targeted drugs in combination with checkpoint inhibitors, chemotherapy, or radiotherapy. 3. Research on Inflammation and Autoimmune Diseases: Explore the role of SIRPα signaling in inflammatory diseases and autoimmune diseases.

1. Immunotherapy Evaluation: Evaluate the efficacy and safety of antibodies, bispecific antibodies, or small molecule drugs targeting the CD47-SIRPα signaling axis. Study the mechanisms and enhancement strategies of macrophage-mediated tumor cell phagocytosis (ADCP). 2. Tumor Immunology: Simulate the immune checkpoint function of CD47 in the human body to study the mechanism of tumor immune escape. Test the synergistic effects of CD47-targeted drugs combined with other immune checkpoint inhibitors such as PD-1/PD-L1. 3. Hematology and Oncology: Study the role of CD47 in hematological tumors such as acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL). Assess the impact of CD47-targeted drugs on normal hematopoietic stem cells and tumor stem cells.

Iron Metabolism and Hematological Disease Research: Investigate the role of human transferrin receptor 1 (TFRC) in iron uptake, erythropoiesis, and the regulation of iron homeostasis. Explore the pathological mechanisms of diseases associated with TFRC dysfunction or dysregulation, such as iron deficiency anemia, hemochromatosis, and certain leukemias. Tumor-Targeted Therapy: Evaluate the efficacy and safety of antibody-drug conjugates, bispecific antibodies, or immunotoxins targeting human TFRC in various tumors with high TFRC expression (e.g., certain leukemias, lymphomas, solid tumors). Study the mechanisms of TFRC-mediated iron-dependent survival and proliferation in tumor cells. Antibody Drug Development and Validation: Serves as a highly clinically relevant humanized model for the preclinical evaluation of the pharmacodynamics, pharmacokinetics, and safety of therapeutic or diagnostic antibodies and nanomedicines targeting human TFRC.

Oncology Research: Investigate the role of cancer-associated fibroblasts and the human fibroblast activation protein they express in tumor growth, invasion, metastasis, and immune evasion. Evaluate the efficacy and safety of novel therapies targeting human FAP, such as antibodies, inhibitors, and cell therapies (e.g., CAR-T, CAR-NK). Fibrotic Disease Research: Study the function of FAP in the development of tissue fibrosis (e.g., pulmonary fibrosis, liver fibrosis, cardiac fibrosis) and test anti-fibrotic therapies targeting FAP. Immunotherapy Evaluation: Serve as an ideal model for preclinical evaluation of therapies targeting human FAP, such as radioligand therapies and bispecific antibodies.

Immunology Research: Investigate the role of human Interleukin-9 Receptor (hIL9R) signaling in regulating immune cell functions (e.g., T cells, mast cells, basophils). Explore the mechanisms of hIL9R in immune-related diseases such as allergy, asthma, and autoimmune disorders. Cancer Immunotherapy: Evaluate the efficacy of targeting the hIL9R/IL-9 axis in tumor immunotherapy (e.g., in combination with checkpoint inhibitors, CAR-T therapy). Establish preclinical models to assess drugs targeting hIL9R (e.g., antibodies, fusion proteins). Inflammatory Disease Research: Study the role of hIL9R signaling in pathological processes like chronic inflammation, pulmonary fibrosis, and enteritis.

Human cell or tissue transplantation；
Hematopoietic and immunological studies；
​Cancer and Cancer Stem Cell Research​；
Human Disease Infection Models Research​​；

Efficacy evaluation of TIGIT inhibitors；
Cancer immunotherapy and autoimmune disease research；
TIGIT Antibody Safety Profile​；
Immunomodulatory Mechanisms of TIGIT Targeting​；

Cardiovascular disease research；
Screening and evaluation of humanized PCSK9 antibodies；

Drug Development​